ZyVet Animal Health, a wholly owned subsidiary of Zydus Pharmaceuticals (USA), has launched the first FDA-approved generic version of phenylpropanolamine hydrochloride tablets for treating urinary incontinence in dogs. The milestone addresses a significant gap in affordable veterinary therapeutics, as fewer than 20% of FDA-approved animal drugs currently have generic alternatives.
Addressing Canine Urinary Incontinence
Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus, a condition frequently affecting spayed females and aging dogs. The condition can lead to frustrating and embarrassing accidents for both pets and their families, impacting quality of life.
ZyVet's generic formulation is available in multiple strengths to support precise dosing and is designed to meet the needs of both veterinary teams and pet owners. The medication provides dependable symptom relief while supporting stronger long-term client compliance through improved affordability.
"Urinary incontinence affects quality of life for both pets and their families," said Punit Patel, President and CEO of Zydus Americas. "Our phenylpropanolamine hydrochloride tablets deliver on both clinical reliability and affordability, enabling veterinarians to confidently treat more patients and maintain client compliance."
Expanding Generic Portfolio
In addition to the phenylpropanolamine launch, ZyVet has received FDA approval for generic furosemide tablets for veterinary use. Furosemide is a commonly prescribed diuretic for managing congestive heart failure and chronic fluid retention in dogs and cats, used to reduce edema and pulmonary congestion caused by cardiac, renal, or systemic disease.
The dual launch represents ZyVet's rapid portfolio expansion in the underserved veterinary generics market. As a division of Zydus Lifesciences, ZyVet leverages more than 70 years of pharmaceutical research and development, regulatory expertise, and manufacturing capabilities.
Market Impact
The launches address a critical need in veterinary medicine, where cost often serves as a barrier to treatment access. Patel emphasized that the company's approach demonstrates "that innovation doesn't need to come with a premium price tag - and that every pet should have access to high-quality treatment options."
ZyVet's expansion reinforces a paradigm shift in the animal health industry, demonstrating that generic veterinary products can match the effectiveness of pioneer brands while providing economic alternatives for long-term disease management. The company positions itself as a leader in bringing affordable innovation to animal care, making essential treatments more accessible for everyday pet owners and their veterinarians.
